What is Resmed's earnings per share (EPS)?

Resmed (RMD) reported diluted earnings per share of $10.43 for fiscal year 2026. This represents a 9.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Resmed Financials

RMD

FY2026 annual

Revenue $5.7B +9.9% YoY

Net Income $1.5B +8.8% YoY

EPS (Diluted) $10.43 +9.7% YoY

Free Cash Flow $1.6B -0.7% YoY

Source SEC Filings (10-K/10-Q) Latest period FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE June

Resmed (RMD) reported $5.7B in revenue for fiscal year 2026, up 9.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI RMD FY2026 2026-08-15

ResMed’s dominant mechanic is profitable growth that converts into cash, funds distributions, and steadily reduces balance-sheet leverage.

The cash story is stronger than the free-cash-flow headline: in FY2026, operating cash flow of $1.81B exceeded net income of $1.52B, so reported earnings were fully cash-backed. FCF margin eased from 32.3% in FY2025 to 29.2% in FY2026 even as operating cash flow increased, because capital spending rose; the modest FCF slowdown therefore reflects reinvestment rather than weaker earnings conversion.

Gross-margin expansion from 55.8% in FY2023 to 61.1% in FY2026 indicates that the business’s unit economics improved rather than merely scaling unchanged. Operating margin climbed from 26.8% to 33.4%, showing that a larger share of incremental sales reached operating profit, consistent with operating leverage.

Debt dependence fell sharply, with debt-to-equity declining from 0.35x in FY2023 to 0.06x in FY2026; the balance sheet is materially less reliant on borrowing. That deleveraging occurred alongside $700M of buybacks and $350M of dividends in FY2026, indicating cash generation funded both capital returns and debt reduction.

Financial Health Signals

Financial Health Score 87/100

Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Resmed's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Resmed has an operating margin of 33.4%, meaning the company retains $33 of operating profit per $100 of revenue. This strong profitability earns a score of 95/100, reflecting efficient cost management and pricing power. This is up from 32.8% the prior year.

Growth

Resmed's revenue grew 9.9% year-over-year to $5.7B, a solid pace of expansion. This earns a growth score of 65/100.

Leverage

Resmed carries a low D/E ratio of 0.06, meaning only $0.06 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.10, Resmed holds $3.10 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 78/100.

Cash Flow

Resmed converts 29.2% of revenue into free cash flow ($1.6B). This strong cash generation earns a score of 94/100.

Returns

Resmed earns a strong 23.1% return on equity (ROE), meaning it generates $23 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 93/100. This is down from 23.5% the prior year.

Altman Z-Score Safe

11.42

Resmed scores 11.42, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($34.0B) relative to total liabilities ($2.4B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

Resmed passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.19x

For every $1 of reported earnings, Resmed generates $1.19 in operating cash flow ($1.8B OCF vs $1.5B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$5.7B

YoY+9.9%

5Y CAGR+12.1%

10Y CAGR+11.9%

Resmed generated $5.7B in revenue in fiscal year 2026. This represents an increase of 9.9% from the prior year.

EBITDA

$2.1B

YoY+10.8%

5Y CAGR+14.5%

10Y CAGR+15.0%

Resmed's EBITDA was $2.1B in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 10.8% from the prior year.

Net Income

$1.5B

YoY+8.8%

5Y CAGR+26.3%

10Y CAGR+15.8%

Resmed reported $1.5B in net income in fiscal year 2026. This represents an increase of 8.8% from the prior year.

EPS (Diluted)

$10.43

YoY+9.7%

Resmed earned $10.43 per diluted share (EPS) in fiscal year 2026. This represents an increase of 9.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$1.6B

YoY-0.7%

5Y CAGR+21.1%

10Y CAGR+12.9%

Resmed generated $1.6B in free cash flow in fiscal year 2026, representing cash available after capex. This represents a decrease of 0.7% from the prior year.

Cash & Debt

$1.5B

YoY+21.5%

5Y CAGR+37.8%

10Y CAGR+7.2%

Resmed held $1.5B in cash against $399.4M in long-term debt as of fiscal year 2026.

Dividends Per Share

$2.40

YoY+13.2%

Resmed paid $2.40 per share in dividends in fiscal year 2026. This represents an increase of 13.2% from the prior year.

Shares Outstanding

144M

YoY-1.5%

Resmed had 144M shares outstanding in fiscal year 2026. This represents a decrease of 1.5% from the prior year.

Margins & Returns

Gross Margin

61.1%

YoY+1.7pp

5Y CAGR+3.5pp

10Y CAGR+3.1pp

Resmed's gross margin was 61.1% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 1.7 percentage points from the prior year.

Operating Margin

33.4%

YoY+0.6pp

5Y CAGR+5.1pp

10Y CAGR+10.0pp

Resmed's operating margin was 33.4% in fiscal year 2026, reflecting core business profitability. This is up 0.6 percentage points from the prior year.

Net Margin

26.9%

YoY-0.3pp

5Y CAGR+12.1pp

10Y CAGR+7.8pp

Resmed's net profit margin was 26.9% in fiscal year 2026, showing the share of revenue converted to profit. This is down 0.3 percentage points from the prior year.

Return on Equity

23.1%

YoY-0.3pp

5Y CAGR+6.7pp

10Y CAGR+2.3pp

Resmed's ROE was 23.1% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 0.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$378.3M

YoY+14.2%

5Y CAGR+10.9%

10Y CAGR+12.3%

Resmed invested $378.3M in research and development in fiscal year 2026. This represents an increase of 14.2% from the prior year.

Share Buybacks

$700.0M

YoY+133.3%

Resmed spent $700.0M on share buybacks in fiscal year 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 133.3% from the prior year.

Capital Expenditures

$156.3M

YoY+73.9%

5Y CAGR+8.8%

10Y CAGR+10.3%

Resmed invested $156.3M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents an increase of 73.9% from the prior year.

RMD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

RMD quarterly income statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Revenue	$5.7B+9.9%	$5.1B+9.8%	$4.7B+10.9%	$4.2B+18.0%	$3.6B+11.9%	$3.2B+8.1%	$3.0B+13.4%	$2.6B+11.4%	$2.3B+13.2%	$2.1B+12.4%	$1.8B+9.5%	$1.7B+8.0%	$1.6B+2.7%	$1.5B+10.7%	$1.4B
Cost of Revenue	$2.2B+5.3%	$2.1B+3.0%	$2.0B+8.7%	$1.9B+20.2%	$1.6B+14.4%	$1.4B+9.6%	$1.2B+11.4%	$1.1B+10.7%	$1.0B+16.2%	$865.0M+12.0%	$772.2M+15.7%	$667.5M+18.1%	$565.2M-1.5%	$573.8M+4.8%	$547.8M
Gross Profit	$3.5B+13.0%	$3.1B+15.1%	$2.7B+12.7%	$2.4B+16.4%	$2.0B+10.1%	$1.8B+7.1%	$1.7B+15.0%	$1.5B+11.9%	$1.3B+11.1%	$1.2B+12.7%	$1.1B+5.4%	$1.0B+2.2%	$989.8M+5.2%	$940.7M+14.6%	$820.7M
R&D Expenses	$378.3M+14.2%	$331.3M+7.7%	$307.5M+6.9%	$287.6M+13.4%	$253.6M+12.6%	$225.3M+11.6%	$201.9M+11.8%	$180.7M+16.4%	$155.1M+7.4%	$144.5M+21.8%	$118.7M+3.3%	$114.9M-2.8%	$118.2M-1.6%	$120.1M+9.5%	$109.7M
SG&A Expenses	$1.1B+12.7%	$993.0M+8.3%	$917.1M+4.9%	$874.0M+18.5%	$737.5M+10.0%	$670.4M-0.9%	$676.7M+4.9%	$645.0M+7.4%	$600.4M+8.4%	$554.0M+13.5%	$488.1M+2.0%	$478.6M+6.3%	$450.4M+4.6%	$430.8M+7.0%	$402.6M
Operating Income	$1.9B+11.9%	$1.7B+27.7%	$1.3B+16.6%	$1.1B+13.2%	$1.0B+10.7%	$903.7M+11.6%	$809.7M+39.8%	$579.3M+6.9%	$541.8M+27.3%	$425.8M-0.7%	$429.0M+4.8%	$409.2M+1.0%	$405.1M+14.2%	$354.8M+20.5%	$294.4M
Interest Expense	N/A	N/A	N/A	-$47.4M-112.3%	-$22.3M-193.0%	$24.0M-40.6%	$40.4M+11.7%	$36.2M+27.5%	$28.4M+0.4%	$28.2M+152.0%	$11.2M+93.9%	$5.8M-5.7%	$6.1M-4.0%	$6.4M+33.5%	$4.8M
Income Tax	$396.1M+43.1%	$276.8M+13.5%	$243.8M+19.5%	$204.1M+12.7%	$181.0M-55.8%	$409.2M+267.2%	$111.4M-2.5%	$114.3M-44.5%	$205.7M+169.1%	$76.5M-12.3%	$87.2M+5.0%	$83.0M-3.2%	$85.8M+10.0%	$78.0M+1.2%	$77.1M
Net Income	$1.5B+8.8%	$1.4B+37.2%	$1.0B+13.7%	$897.6M+15.2%	$779.4M+64.3%	$474.5M-23.7%	$621.7M+53.7%	$404.6M+28.2%	$315.6M-7.8%	$342.3M-2.9%	$352.4M-0.1%	$352.9M+2.2%	$345.3M+12.4%	$307.1M+20.5%	$254.8M
EPS (Diluted)	$10.43+9.7%	$9.51+37.4%	$6.92+13.6%	$6.09+14.9%	$5.30	$3.24	$4.27+52.5%	$2.80+27.9%	$2.19-8.8%	$2.40-3.6%	$2.49+0.8%	$2.47+3.3%	$2.39+13.8%	$2.10+22.8%	$1.71

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Revenue	$1.5B+2.3%	$1.4B+0.6%	$1.4B+6.5%	$1.3B-0.9%	$1.3B+4.4%	$1.3B+0.8%	$1.3B+4.7%	$1.2B
Cost of Revenue	$602.4M+11.5%	$540.4M-0.7%	$544.1M+5.7%	$514.8M-2.5%	$527.9M+0.5%	$525.3M-1.0%	$530.8M+4.6%	$507.3M
Gross Profit	$861.2M-3.3%	$891.0M+1.4%	$878.7M+7.1%	$820.8M+0.1%	$820.1M+7.0%	$766.4M+2.0%	$751.3M+4.7%	$717.2M
R&D Expenses	$105.7M+12.2%	$94.3M+3.6%	$91.0M+4.2%	$87.3M+1.0%	$86.4M+3.0%	$83.9M+3.2%	$81.4M+2.3%	$79.5M
SG&A Expenses	$296.3M+3.7%	$285.7M+2.6%	$278.4M+7.4%	$259.2M-3.0%	$267.2M+8.9%	$245.3M+1.5%	$241.6M+1.1%	$239.0M
Operating Income	$448.7M-10.2%	$499.8M+1.7%	$491.7M+10.1%	$446.5M-1.8%	$454.5M+6.6%	$426.3M+2.2%	$417.2M+7.7%	$387.3M
Income Tax	$90.7M-12.4%	$103.6M0.0%	$103.6M+5.4%	$98.3M+25.4%	$78.3M+48.8%	$52.7M-28.6%	$73.7M+2.2%	$72.1M
Net Income	$383.4M-3.8%	$398.7M+1.6%	$392.6M+12.6%	$348.5M-8.2%	$379.7M+4.0%	$365.0M+5.9%	$344.6M+10.7%	$311.4M
EPS (Diluted)	$2.64-3.6%	$2.74+2.2%	$2.68+13.1%	$2.37-8.1%	$2.58+4.0%	$2.48+6.0%	$2.34+10.9%	$2.11

Not reported in any period shown, so not listed: Interest Expense.

RMD Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

RMD quarterly balance sheet

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Total Assets	$9.0B+9.7%	$8.2B+18.9%	$6.9B+1.8%	$6.8B+32.5%	$5.1B+7.8%	$4.7B+3.1%	$4.6B+11.7%	$4.1B+34.1%	$3.1B-11.7%	$3.5B+6.5%	$3.3B+49.3%	$2.2B-7.6%	$2.4B+6.8%	$2.2B+3.4%	$2.1B
Current Assets	$4.3B+23.4%	$3.5B+48.7%	$2.4B-0.4%	$2.4B+22.6%	$1.9B+22.7%	$1.6B+3.4%	$1.5B+33.0%	$1.1B+7.5%	$1.1B-35.2%	$1.6B+15.8%	$1.4B+0.8%	$1.4B-9.5%	$1.6B+7.4%	$1.4B+6.4%	$1.4B
Cash & Equivalents	$1.5B+21.5%	$1.2B+407.4%	$238.4M+4.6%	$227.9M-16.7%	$273.7M-7.3%	$295.3M-36.2%	$463.2M+214.8%	$147.1M-22.0%	$188.7M-77.0%	$821.9M+12.4%	$731.4M+2.0%	$717.2M-20.8%	$905.7M+3.4%	$876.0M+8.2%	$809.5M
Inventory	$945.8M+2.0%	$927.7M+12.8%	$822.3M-17.6%	$998.0M+34.2%	$743.9M+62.8%	$457.0M+9.6%	$416.9M+19.2%	$349.6M+30.1%	$268.7M+0.1%	$268.3M+19.5%	$224.5M-9.1%	$246.9M+49.2%	$165.4M+13.4%	$145.8M-16.3%	$174.4M
Accounts Receivable	$1.0B+10.3%	$939.5M+12.2%	$837.3M+18.8%	$704.9M+22.4%	$576.0M-6.2%	$614.3M+29.4%	$474.6M-10.2%	$528.5M+9.3%	$483.7M+7.4%	$450.5M+17.9%	$382.1M+5.4%	$362.6M+0.8%	$359.6M+13.0%	$318.3M	N/A
Goodwill	$2.9B-4.5%	$3.0B+7.2%	$2.8B+2.6%	$2.8B+43.1%	$1.9B+0.4%	$1.9B+2.0%	$1.9B+1.8%	$1.9B+73.7%	$1.1B+0.4%	$1.1B+0.5%	$1.1B+300.8%	$264.3M-8.7%	$289.3M+5.3%	$274.8M+7.3%	$256.2M
Total Liabilities	$2.4B+7.9%	$2.2B+9.9%	$2.0B-23.4%	$2.6B+51.1%	$1.7B-5.8%	$1.8B-11.9%	$2.1B+2.7%	$2.0B+102.5%	$1.0B-33.4%	$1.5B-3.4%	$1.6B+162.7%	$594.5M-1.4%	$602.7M+0.4%	$600.2M+13.2%	$530.2M
Current Liabilities	$1.4B+36.9%	$1.0B+11.9%	$910.7M+20.1%	$758.5M+10.0%	$689.3M-24.4%	$911.8M+51.3%	$602.8M+8.4%	$556.0M+8.8%	$511.2M+42.0%	$360.1M-43.6%	$638.0M+139.4%	$266.5M-1.1%	$269.6M-53.0%	$574.0M+127.0%	$252.9M
Long-Term Debt	$399.4M-39.3%	$658.4M-5.6%	$697.3M-51.3%	$1.4B+87.0%	$765.3M+19.0%	$643.4M-44.7%	$1.2B-7.5%	$1.3B+366.3%	$270.0M-75.0%	$1.1B+23.5%	$873.3M+190.5%	$300.6M-0.1%	$300.8M	N/A	$250.8M
Total Equity	$6.6B+10.3%	$6.0B+22.7%	$4.9B+17.8%	$4.1B+22.9%	$3.4B+16.5%	$2.9B+15.6%	$2.5B+20.5%	$2.1B+0.6%	$2.1B+5.0%	$2.0B+15.7%	$1.7B+6.8%	$1.6B-9.7%	$1.8B+9.2%	$1.6B+0.2%	$1.6B
Retained Earnings	$7.3B+19.3%	$6.1B+21.8%	$5.0B+17.4%	$4.3B+17.7%	$3.6B+17.3%	$3.1B+8.7%	$2.8B+16.3%	$2.4B+0.2%	$2.4B+5.0%	$2.3B+7.2%	$2.2B+9.3%	$2.0B+11.0%	$1.8B+12.9%	$1.6B+15.4%	$1.4B

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Total Assets	$9.0B+2.1%	$8.8B+3.3%	$8.5B+2.3%	$8.3B+1.6%	$8.2B+8.0%	$7.6B+6.0%	$7.1B-1.1%	$7.2B
Current Assets	$4.3B+6.4%	$4.1B+6.4%	$3.8B+5.3%	$3.6B+3.4%	$3.5B+9.3%	$3.2B+13.1%	$2.8B+7.4%	$2.6B
Cash & Equivalents	$1.5B-11.5%	$1.7B+17.2%	$1.4B+2.4%	$1.4B+14.4%	$1.2B+29.7%	$932.7M+78.7%	$521.9M+22.4%	$426.4M
Inventory	$945.8M+3.7%	$911.9M-1.1%	$922.0M-2.5%	$945.8M+2.0%	$927.7M+7.5%	$862.6M-2.2%	$882.1M-3.9%	$918.0M
Accounts Receivable	$1.0B+3.7%	$998.8M+1.3%	$985.6M+8.6%	$907.3M-3.4%	$939.5M+3.5%	$907.8M+5.6%	$859.9M+6.0%	$811.2M
Goodwill	$2.9B-4.4%	$3.0B0.0%	$3.0B0.0%	$3.0B-0.1%	$3.0B+6.9%	$2.8B+1.6%	$2.8B-2.8%	$2.9B
Total Liabilities	$2.4B+3.8%	$2.3B+5.0%	$2.2B-0.2%	$2.2B-0.9%	$2.2B+9.2%	$2.0B+7.0%	$1.9B-6.9%	$2.0B
Current Liabilities	$1.4B+3.2%	$1.4B+8.3%	$1.2B-0.6%	$1.3B+23.2%	$1.0B+8.4%	$940.5M+10.4%	$852.0M-5.8%	$904.1M
Long-Term Debt	$399.4M-1.2%	$404.2M+0.1%	$403.9M-1.2%	$408.7M-37.9%	$658.4M-0.7%	$663.1M0.0%	$662.9M-0.7%	$667.6M
Total Equity	$6.6B+1.4%	$6.5B+2.7%	$6.3B+3.3%	$6.1B+2.6%	$6.0B+7.6%	$5.5B+5.6%	$5.3B+1.1%	$5.2B
Retained Earnings	$7.3B+4.3%	$7.0B+4.7%	$6.6B+4.8%	$6.3B+4.3%	$6.1B+5.2%	$5.8B+5.2%	$5.5B+5.1%	$5.2B

RMD Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

RMD quarterly cash flow statement

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Operating Cash Flow	$1.8B+3.1%	$1.8B+25.0%	$1.4B+102.1%	$693.3M+97.4%	$351.1M-52.3%	$736.7M-8.2%	$802.3M+74.8%	$459.1M-9.1%	$505.0M+22.0%	$414.1M-24.4%	$547.9M+43.0%	$383.2M-2.1%	$391.3M-2.9%	$402.8M+5.1%	$383.2M
Capital Expenditures	$156.3M+73.9%	$89.9M-9.6%	$99.5M-16.9%	$119.7M-11.2%	$134.8M+31.3%	$102.7M+7.7%	$95.3M+38.7%	$68.7M+9.8%	$62.6M+0.6%	$62.2M+6.3%	$58.5M-6.3%	$62.5M-14.1%	$72.7M+14.4%	$63.6M+34.9%	$47.1M
Free Cash Flow	$1.6B-0.7%	$1.7B+27.6%	$1.3B+126.9%	$573.6M+165.2%	$216.3M-65.9%	$634.0M-10.3%	$706.9M+81.1%	$390.3M-11.8%	$442.4M+25.8%	$351.8M-28.1%	$489.4M+52.6%	$320.7M+0.7%	$318.5M-6.1%	$339.2M+1.0%	$336.0M
Investing Cash Flow	-$545.2M-172.5%	-$200.0M+25.8%	-$269.8M+76.7%	-$1.2B-404.5%	-$229.9M-45.1%	-$158.5M+11.9%	-$179.9M+83.3%	-$1.1B-956.4%	-$101.8M-24.3%	-$81.9M+92.7%	-$1.1B	N/A	N/A	-$78.0M+23.2%	-$101.6M
Financing Cash Flow	-$1.0B-66.1%	-$606.3M+45.8%	-$1.1B-364.7%	$422.9M+429.4%	-$128.4M+83.2%	-$764.6M-141.0%	-$317.3M-154.6%	$580.6M+156.6%	-$1.0B-290.6%	-$262.9M-142.9%	$612.6M	N/A	N/A	-$153.9M+13.1%	-$177.1M
Dividends Paid	$349.7M+12.5%	$310.9M+10.1%	$282.3M+9.3%	$258.3M+5.3%	$245.3M+8.2%	$226.7M+0.7%	$225.1M+6.3%	$211.7M+6.1%	$199.5M+7.1%	$186.3M+10.8%	$168.1M+6.9%	$157.3M+11.1%	$141.5M+45.6%	$97.2M	N/A
Share Buybacks	$700.0M+133.3%	$300.0M+100.0%	$150.0M	$0	$0	N/A	N/A	$22.8M-57.5%	$53.8M	N/A	$102.1M-36.3%	$160.3M-20.7%	$202.2M+8.5%	$186.3M-52.6%	$392.7M

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Operating Cash Flow	$454.6M-18.0%	$554.1M+63.1%	$339.7M-25.7%	$457.3M-15.1%	$538.8M-6.9%	$578.7M+87.5%	$308.6M-5.2%	$325.5M
Capital Expenditures	$51.1M+51.9%	$33.7M+17.9%	$28.5M-33.6%	$43.0M+40.5%	$30.6M+47.1%	$20.8M+0.7%	$20.6M+15.7%	$17.8M
Free Cash Flow	$403.5M-22.5%	$520.5M+67.2%	$311.2M-24.9%	$414.4M-18.5%	$508.2M-8.9%	$557.9M+93.7%	$288.0M-6.4%	$307.7M
Investing Cash Flow	-$383.7M-561.1%	-$58.0M-13.9%	-$50.9M+3.1%	-$52.6M+60.7%	-$133.7M-320.7%	-$31.8M+13.4%	-$36.7M-1809.8%	$2.1M
Financing Cash Flow	-$263.2M-3.1%	-$255.2M+1.2%	-$258.3M-12.2%	-$230.3M-40.5%	-$163.9M-13.8%	-$144.1M+2.3%	-$147.5M+2.1%	-$150.8M
Dividends Paid	$87.1M-0.2%	$87.2M-0.4%	$87.6M-0.2%	$87.8M+13.1%	$77.6M-0.1%	$77.7M0.0%	$77.7M-0.3%	$77.9M
Share Buybacks	$200.0M+14.3%	$175.0M0.0%	$175.0M+16.7%	$150.0M+50.0%	$100.0M+33.3%	$75.0M+0.1%	$75.0M+50.0%	$50.0M

RMD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

RMD quarterly financial ratios

Metric	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12
Gross Margin	61.1%+1.7pp	59.4%+2.7pp	56.7%+0.9pp	55.8%-0.8pp	56.6%-1.0pp	57.5%-0.6pp	58.1%+0.8pp	57.3%+0.3pp	57.0%-1.1pp	58.1%+0.2pp	58.0%-2.2pp	60.2%-3.4pp	63.6%+1.5pp	62.1%+2.1pp	60.0%
Operating Margin	33.4%+0.6pp	32.8%+4.6pp	28.2%+1.4pp	26.8%-1.2pp	28.0%-0.3pp	28.3%+0.9pp	27.4%+5.2pp	22.2%-0.9pp	23.2%+2.6pp	20.6%-2.7pp	23.3%-1.0pp	24.4%-1.7pp	26.1%+2.6pp	23.4%+1.9pp	21.5%
Net Margin	26.9%-0.3pp	27.2%+5.4pp	21.8%+0.5pp	21.3%-0.5pp	21.8%+6.9pp	14.8%-6.2pp	21.0%+5.5pp	15.5%+2.0pp	13.5%-3.1pp	16.6%-2.6pp	19.2%-1.8pp	21.0%-1.2pp	22.2%+1.9pp	20.3%+1.7pp	18.6%
Return on Equity	23.1%-0.3pp	23.5%+2.5pp	21.0%-0.7pp	21.7%-1.5pp	23.2%+6.8pp	16.4%-8.5pp	24.9%+5.4pp	19.5%+4.2pp	15.3%-2.1pp	17.5%-3.3pp	20.8%-1.4pp	22.2%+2.6pp	19.6%+0.6pp	19.1%+3.2pp	15.8%
Return on Assets	17.0%-0.2pp	17.1%+2.3pp	14.9%+1.6pp	13.3%-2.0pp	15.3%+5.3pp	10.0%-3.5pp	13.6%+3.7pp	9.8%-0.4pp	10.3%+0.4pp	9.9%-1.0pp	10.8%-5.4pp	16.2%+1.6pp	14.6%+0.7pp	13.9%+2.0pp	11.9%
Current Ratio	3.10-0.3x	3.44+0.9x	2.59-0.5x	3.12+0.3x	2.80+1.1x	1.73-0.8x	2.53+0.5x	2.060.0x	2.08-2.5x	4.57+2.3x	2.23-3.1x	5.28-0.5x	5.77+3.2x	2.52-2.9x	5.38
Debt-to-Equity	0.060.0x	0.110.0x	0.14-0.2x	0.35+0.1x	0.230.0x	0.22-0.2x	0.47-0.1x	0.61+0.5x	0.13-0.4x	0.550.0x	0.52+0.3x	0.190.0x	0.17-0.2x	0.37+0.2x	0.16
FCF Margin	29.2%-3.1pp	32.3%+4.5pp	27.8%+14.2pp	13.6%+7.5pp	6.0%-13.8pp	19.8%-4.1pp	23.9%+8.9pp	15.0%-3.9pp	18.9%+1.9pp	17.0%-9.6pp	26.6%+7.5pp	19.1%-1.4pp	20.5%-1.9pp	22.4%-2.1pp	24.6%

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Gross Margin	58.8%-3.4pp	62.3%+0.5pp	61.8%+0.3pp	61.5%+0.6pp	60.8%+1.5pp	59.3%+0.7pp	58.6%0.0pp	58.6%
Operating Margin	30.7%-4.3pp	34.9%+0.4pp	34.6%+1.1pp	33.4%-0.3pp	33.7%+0.7pp	33.0%+0.5pp	32.5%+0.9pp	31.6%
Net Margin	26.2%-1.7pp	27.9%+0.3pp	27.6%+1.5pp	26.1%-2.1pp	28.2%-0.1pp	28.3%+1.4pp	26.9%+1.4pp	25.4%
Return on Equity	5.8%-0.3pp	6.1%-0.1pp	6.2%+0.5pp	5.7%-0.7pp	6.4%-0.2pp	6.6%0.0pp	6.6%+0.6pp	6.0%
Return on Assets	4.3%-0.3pp	4.5%-0.1pp	4.6%+0.4pp	4.2%-0.4pp	4.7%-0.2pp	4.8%0.0pp	4.8%+0.5pp	4.3%
Current Ratio	3.10+0.1x	3.01-0.1x	3.06+0.2x	2.89-0.6x	3.440.0x	3.41+0.1x	3.33+0.4x	2.92
Debt-to-Equity	0.060.0x	0.060.0x	0.060.0x	0.070.0x	0.110.0x	0.120.0x	0.130.0x	0.13
FCF Margin	27.6%-8.8pp	36.4%+14.5pp	21.9%-9.1pp	31.0%-6.7pp	37.7%-5.5pp	43.2%+20.7pp	22.5%-2.7pp	25.1%

Similar Companies

Alcon Inc ALC

$35.5B

Becton Dickinson & Co BDX

$51.7B

West Pharm Svcs WST

$24.5B

Hologic Inc HOLX

$17.0B

Solventum Corporation SOLV

$15.6B

Where Resmed Ranks

Frequently Asked Questions

What is Resmed's annual revenue?

Resmed (RMD) reported $5.7B in total revenue for fiscal year 2026. This represents a 9.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Resmed's revenue growing?

Resmed (RMD) revenue grew by 9.9% year-over-year, from $5.1B to $5.7B in fiscal year 2026.

Is Resmed profitable?

Yes, Resmed (RMD) reported a net income of $1.5B in fiscal year 2026, with a net profit margin of 26.9%.

What is Resmed's EBITDA?

Resmed (RMD) had EBITDA of $2.1B in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Resmed have?

As of fiscal year 2026, Resmed (RMD) had $1.5B in cash and equivalents against $399.4M in long-term debt.

What is Resmed's gross margin?

Resmed (RMD) had a gross margin of 61.1% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is Resmed's operating margin?

Resmed (RMD) had an operating margin of 33.4% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is Resmed's net profit margin?

Resmed (RMD) had a net profit margin of 26.9% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

Does Resmed pay dividends?

Yes, Resmed (RMD) paid $2.40 per share in dividends during fiscal year 2026.

What is Resmed's return on equity (ROE)?

Resmed (RMD) has a return on equity of 23.1% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is Resmed's free cash flow?

Resmed (RMD) generated $1.6B in free cash flow during fiscal year 2026. This represents a -0.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Resmed's operating cash flow?

Resmed (RMD) generated $1.8B in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are Resmed's total assets?

Resmed (RMD) had $9.0B in total assets as of fiscal year 2026, including both current and long-term assets.

What are Resmed's capital expenditures?

Resmed (RMD) invested $156.3M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does Resmed spend on research and development?

Resmed (RMD) invested $378.3M in research and development during fiscal year 2026.

Does Resmed buy back shares?

Yes, Resmed (RMD) spent $700.0M on share buybacks during fiscal year 2026, returning capital to shareholders by reducing shares outstanding.

How many shares does Resmed have outstanding?

Resmed (RMD) had 144M shares outstanding as of fiscal year 2026.

What is Resmed's current ratio?

Resmed (RMD) had a current ratio of 3.10 as of fiscal year 2026, which is generally considered healthy.

What is Resmed's debt-to-equity ratio?

Resmed (RMD) had a debt-to-equity ratio of 0.06 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Resmed's return on assets (ROA)?

Resmed (RMD) had a return on assets of 17.0% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is Resmed's Altman Z-Score?

Resmed (RMD) has an Altman Z-Score of 11.42, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Resmed's Piotroski F-Score?

Resmed (RMD) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Resmed's earnings high quality?

Resmed (RMD) has an earnings quality ratio of 1.19x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Resmed?

Resmed (RMD) scores 87 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.